Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 6/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 6/20 | 0.50 |
| ▸ | FEN1 | P39748 | 6/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150174 | 0.84 | STIM1 (0.50) | STIM1ORAI1SCN9AGPR55ORAI2 | |
| SCHEMBL1701937 | 0.84 | STIM1 (0.56) | STIM1ORAI1FEN1SCN9AGPR55 | |
| SCHEMBL14881412 | 0.78 | STIM1 (0.46) | STIM1ORAI1PIK3CASCN9AGPR3 | |
| SCHEMBL1702358 | 0.76 | STIM1 (0.55) | STIM1ORAI1FEN1ALOX5APORAI2 | |
| SCHEMBL14150229 | 0.72 | STIM1 (0.80) | STIM1ORAI1SCN9AGPR55ORAI2 | |
| SCHEMBL14225998 | 0.72 | STIM1 (0.64) | STIM1ORAI1SCN9AGPR55ORAI2 | |
| SCHEMBL14225999 | 0.71 | STIM1 (0.62) | STIM1ORAI1SCN9AORAI2ALDH1A1 | |
| SCHEMBL14881322 | 0.71 | STIM1 (0.43) | STIM1ORAI1SCN9AGPR3 | |
| SCHEMBL8239476 | 0.71 | TSHR (0.39) | STIM1ORAI1PIK3CASCN9AGPR3 | |
| SCHEMBL16076086 | 0.70 | TSHR (0.42) | STIM1ORAI1PIK3CAGPR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106529-B2 | Compounds that modulate intracellular calcium | CALCIMEDIA, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012170931-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170931-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106529-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885FEN1 4618/4885 |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885FEN1 4618/4885 |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885FEN1 4618/4885 |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885FEN1 4618/4885 |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885FEN1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.